SCF β-TRCP targets MTSS1 for ubiquitination-mediated destruction to regulate cancer cell proliferation and migration

Jiateng Zhong1, Shavali Shaik, Lixin Wan

  • 1Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

Oncotarget
|December 10, 2013
PubMed

Insights

Metastasis suppressor 1 (MTSS1) protein degradation is regulated by SCFβ-TRCP, impacting aggressive breast and prostate cancers. Preventing MTSS1 breakdown may offer a new clinical strategy.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • Metastasis suppressor 1 (MTSS1) is a tumor suppressor protein with reduced expression in aggressive human cancers, linked to poor survival.
  • The regulatory mechanisms of MTSS1 in cancer cells and the impact of its reduced expression on cancer progression remain largely unknown.

Purpose of the Study:

  • To elucidate the molecular mechanisms regulating MTSS1 protein stability in cancer cells.
  • To investigate the role of MTSS1 degradation in breast and prostate cancer proliferation and migration.

Main Methods:

  • Investigated MTSS1 regulation using ubiquitination assays, proteasome inhibition, and Western blotting.
  • Utilized genetic depletion of SCF components (Cullin 1, β-TRCP1) and site-directed mutagenesis (Ser322).
  • Assessed the effects of wild-type and mutant MTSS1 expression on cancer cell proliferation and migration.

Main Results:

  • The SCFβ-TRCP E3 ubiquitin ligase complex targets MTSS1 for degradation via the 26S proteasome.
  • Casein Kinase Iδ (CKIδ) phosphorylates MTSS1 at Ser322, initiating β-TRCP binding and subsequent degradation.
  • Restoration of MTSS1, particularly a non-degradable mutant (S322A), significantly inhibited proliferation and migration in cancer cells with low MTSS1 levels.

Conclusions:

  • Identified a novel regulatory pathway where SCFβ-TRCP controls MTSS1 stability through CKIδ-mediated phosphorylation at Ser322.
  • Demonstrated that inhibiting MTSS1 degradation can suppress aggressive cancer phenotypes.
  • Proposed targeting MTSS1 degradation as a potential therapeutic strategy for breast and prostate cancers.

Related Concept Videos

Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K